GSK adds to its trove of positive data for multiple myeloma contender as rivals continue to command the spotlight
GlaxoSmithKline’s cancer R&D team put up more positive numbers for its ADC belantamab mafodotin, one of its top pipeline prospects.
Flashing the results just ahead of a busy ASCO weekend, Axel Hoos and the team noted new multiple myeloma data highlighting promising responses from their open-label DREAMM-6 study — after confirming the overall response rate of 32% among heavily pre-treated patients reviewed in DREAMM-2.
Combined with bortezomib/dexamethasone, belantamab mafodotin hit an overall response rate of 78% among patients who had received one or more previous therapies. That covers 14 out of 18 patients, with “50% achieving a very good partial response and 28% achieving a partial response.”
Jefferies’ Biren Amin was intrigued, but sees some chinks in the GSK armor here:
(S)afety could be problematic with high rates of Gr 3 corneal events and thrombocytopenia at the lower 2.5 mg/kg dose cohort. Today’s release makes no mention of data at the higher 3.4 mg/kg dose nor data from single administration vs split dosing and we await add’l data at ASCO Virtual Meeting.
GSK is looking to clear a path for itself in a crowded field, where the CAR-Ts from bluebird/Bristol Myers and J&J/Legend have been in the spotlight. The rival data looks better, but GSK is coming up from behind with respectable results that will likely have little trouble passing muster.
Once on the market, GSK R&D chief Hal Barron expects their easier availability will give them an edge over the more complicated treatments edging up to approvals.